Switch to vortioxetine or agomelatine if MDD patient with SSRI is experiencing sexual dysfunction?
Incidence of sexual dysfunction across 12 antidepressants
DSM-5, The Diagnostic and Statistic Manual of Mental Disorders, Fifth Edition; MDD, Major depressive disorder.
Florido et al. ECNP 2019, Poster P.023.
In the prospective observational study conducted by Florido et al. on the incidence of sexual dysfunction across 12 commonly used antidepressants, vortioxetine and agomelatine were associated with lower incidences of sexual dysfunction compared to other antidepressants.1 In the instance where a patient is suffering from SSRI-induced sexual dysfunction, switching to an antidepressant of another class that is associated with fewer sexual side effects with the ability to improve all symptomatic domains of MDD may be a viable treatment option.
Brintellix® (vortioxetine) is superior to agomelatine in treating partial responders to previous antidepressant
DSM-5, The Diagnostic and Statistic Manual of Mental Disorders, Fifth Edition; MDD, Major depressive disorder.
Florido et al. ECNP 2019, Poster P.023.
In the prospective observational study conducted by Florido et al. on the incidence of sexual dysfunction across 12 commonly used antidepressants, vortioxetine and agomelatine were associated with lower incidences of sexual dysfunction compared to other antidepressants.1 In the instance where a patient is suffering from SSRI-induced sexual dysfunction, switching to an antidepressant of another class that is associated with fewer sexual side effects with the ability to improve all symptomatic domains of MDD may be a viable treatment option.
Brintellix® (vortioxetine) is superior to agomelatine in treating partial responders to previous antidepressant
*As measured by MADRS; FAS, MMRM by visit and LOCF (FAS, ANCOVA) at Week 8.
**p<0.01; ***p<0.001 vs. agomelatine.
Montgomery SA et al. Hum Psychopharmacol Clin Exp. 2014;29(5):470–482
In a study by Montgomery SA et al., Brintellix® was superior to agomelatine in improving MDD symptoms in patients with partial response to an SSRI or SNRI, as measured by the MADRS.2† Brintellix® had no effect relative to placebo on body weight, cardiovascular adverse event, and no clinical significant changes on hepatic or renal parameters.3 Additionally, Brintellix® was superior to escitalopram in improving SSRI-induced treatment-emergent sexual dysfunction (TESD) in all 5 dimensions and 3 phases as assessed using the CSFQ-14 while efficacy measured with MADRS was maintained.4‡ Brintellix® may be a viable option for a patient with partial response to an initial SSRI treatment and suffering from associated sexual dysfunction.
Brintellix® improved sexual dysfunction in most dimensions and phases unlike other antidepressants
*As measured by MADRS; FAS, MMRM by visit and LOCF (FAS, ANCOVA) at Week 8.
**p<0.01; ***p<0.001 vs. agomelatine.
Montgomery SA et al. Hum Psychopharmacol Clin Exp. 2014;29(5):470–482
In a study by Montgomery SA et al., Brintellix® was superior to agomelatine in improving MDD symptoms in patients with partial response to an SSRI or SNRI, as measured by the MADRS.2† Brintellix® had no effect relative to placebo on body weight, cardiovascular adverse event, and no clinical significant changes on hepatic or renal parameters.3 Additionally, Brintellix® was superior to escitalopram in improving SSRI-induced treatment-emergent sexual dysfunction (TESD) in all 5 dimensions and 3 phases as assessed using the CSFQ-14 while efficacy measured with MADRS was maintained.4‡ Brintellix® may be a viable option for a patient with partial response to an initial SSRI treatment and suffering from associated sexual dysfunction.
Brintellix® improved sexual dysfunction in most dimensions and phases unlike other antidepressants
CSFQ-14, Changes in Sexual Functioning Questionnaire; LS, Least squares; MMRM, mixed model for repeated measures.
Jacobsen PL et al. J Sex Med. 2015;12(10):2036–48.
CSFQ-14, Changes in Sexual Functioning Questionnaire; LS, Least squares; MMRM, mixed model for repeated measures.
Jacobsen PL et al. J Sex Med. 2015;12(10):2036–48.
†Patients were previously treated with one course of citalopram, escitalopram, paroxetine, sertraline, duloxetine or venlafaxine
‡The study included well-treated patients with MDD who were in remission for depressive symptoms but were experiencing sexual
dysfunction while being treated with the SSRIs citalopram, sertraline or paroxetine.
Abbreviations
SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor; MDD, major depressive disorder; MADRS,
Montgomery-Åsberg Depression Rating Scale; CSFQ-14, Changes in Sexual Functioning Questionnaire Short Form; TESD,
treatment-emergent sexual dysfunction
†Patients were previously treated with one course of citalopram, escitalopram, paroxetine, sertraline, duloxetine or venlafaxine ‡The study included well-treated patients with MDD who were in remission for depressive symptoms but were experiencing sexual dysfunction while being treated with the SSRIs citalopram, sertraline or paroxetine.
Abbreviations
SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor; MDD, major depressive disorder; MADRS,
Montgomery-Åsberg Depression Rating Scale; CSFQ-14, Changes in Sexual Functioning Questionnaire Short Form; TESD,
treatment-emergent sexual dysfunction